PTM-001: glycan targeting antibody for the treatment of Inflammatory Bowel Disease (IBD)/Ulcerative Colitis (UC)

PTM-001 specifically binds to the inflamed colonic epithelium in Ulcerative Colitis and Crohn’s Colitis patient samples. There is no significant PTM-001 staining on the disease adjacent normal tissue in the same patient samples.

  • PTM-001 targeted glycan epitope is found on human and mouse intestinal epithelial tissue

  • Due to the ability of PTM-001 to bind to mouse tissue, PTM-001 was used in DSS induced mouse colitis models

  • In the 8 day DSS studies, PTM-001 was found to be efficacious and well tolerated (10mg/kg dose administered via an i.p. injection)

    • PTM-001 treated mice had more normal intestinal morphology when compared to IgG treated mice (IgG treated mice demonstrated severe erosion/loss of intestinal epithelium)

    • PTM-001 treated mice had less severe weight loss and lower disease activity index (DAI) scores when compared to IgG treated mice

  • The improvement or preservation of intestinal morphology and histology in PTM-001 treated animals suggests PTM-001 mechanism of action to be based in mucosal epithelial repair/restitution

  • This is an area of IBD treatment that has not been extensively explored

Table modified from Berinstein J.A., et al., Practical Gastroenterology, April 2019, Vol. XLIII No. 4, 24-62